Please login to the form below

Not currently logged in
Email:
Password:

Philadelphia chromosome positive acute lymphoblastic leukaemia

This page shows the latest Philadelphia chromosome positive acute lymphoblastic leukaemia news and features for those working in and with pharma, biotech and healthcare.

EMA to review safety of Ariad’s Iclusig

EMA to review safety of Ariad’s Iclusig

The PRAC also recommend that the product information be updated for Iclusig, which was approved in the EU in July to treat patients with chronic myeloid leukaemia (CML) and Philadelphia-chromosome ... positive acute lymphoblastic leukaemia (Ph+ ALL).

Latest news

  • Ariad cuts 160 jobs in US after Iclusig suspension Ariad cuts 160 jobs in US after Iclusig suspension

    The authorisations cover use of the drug to treat adults with advanced forms of chronic myeloid leukaemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL).

  • FDA suspends sale of Ariad’s cancer drug FDA suspends sale of Ariad’s cancer drug

    The US Food and Drug Administration (FDA) has asked Ariad to suspend sales of its leukaemia drug Iclusig as it continues to investigate reports of life-threatening side effects. ... accelerated phase, or blast phase CML or Philadelphia

  • Ariad tanks as Iclusig trial is halted on safety grounds Ariad tanks as Iclusig trial is halted on safety grounds

    Ariad tanks as Iclusig trial is halted on safety grounds. Shares fall after leukaemia patients develop blood clots. ... accelerated phase, or blast phase CML or Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL), who are no longer

  • Ariad halts patient enrolment for cancer drug studies Ariad halts patient enrolment for cancer drug studies

    Iclusig (ponatinib) received early approval in the US last year for the treatment of advanced chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), under the proviso

  • Ariad gets EU green light for leukaemia drug Iclusig Ariad gets EU green light for leukaemia drug Iclusig

    The EC gave the go-ahead for Iclusig (ponatinib) as another treatment option for patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... Japan. Meanwhile, it is also focusing on

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... As for the future of Iclusig in leukaemia, Ariad is keen to roll out the drug in Europe over the next few months, while regulatory

More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Ariad founder Harvey Berger to retire as CEO and chairman Ariad founder Harvey Berger to retire as CEO and chairman

    Under his leadership, Ariad brought Iclusig to the market for the treatment of patients with refractory chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, approved in the US, EU,

  • Hugh Cole leaves Shire for Ariad Hugh Cole leaves Shire for Ariad

    This includes its only current marketed product Iclusig, which is recommended to treat chronic myeloid leukaemia and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukaemia.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics